|
Abcellera Biologics Inc. (ABCL) DCF -Bewertung
CA | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
AbCellera Biologics Inc. (ABCL) Bundle
Als Anleger oder Analyst ist der DCF-Taschenrechner von Abcellera Biologics Inc. (ABCL) Ihre Anlaufstelle für eine genaue Bewertung. Mit realen Daten von Abcellera können Sie Prognosen anpassen und die Effekte in Echtzeit beobachten.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 233.2 | 375.2 | 485.4 | 38.0 | 28.8 | 27.0 | 25.2 | 23.6 | 22.0 | 20.6 |
| Revenue Growth, % | 0 | 60.92 | 29.38 | -92.17 | -24.17 | -6.51 | -6.51 | -6.51 | -6.51 | -6.51 |
| EBITDA | 169.6 | 241.6 | 272.2 | -192.2 | -109.5 | -.4 | -.3 | -.3 | -.3 | -.3 |
| EBITDA, % | 72.75 | 64.4 | 56.07 | -505.35 | -379.93 | -1.36 | -1.36 | -1.36 | -1.36 | -1.36 |
| Depreciation | 5.3 | 17.3 | 33.1 | 30.9 | 90.9 | 10.5 | 9.8 | 9.2 | 8.6 | 8.0 |
| Depreciation, % | 2.26 | 4.6 | 6.82 | 81.25 | 315.09 | 38.98 | 38.98 | 38.98 | 38.98 | 38.98 |
| EBIT | 164.3 | 224.4 | 239.1 | -223.1 | -200.4 | -1.1 | -1.0 | -1.0 | -.9 | -.8 |
| EBIT, % | 70.49 | 59.8 | 49.26 | -586.59 | -695.02 | -4.09 | -4.09 | -4.09 | -4.09 | -4.09 |
| Total Cash | 594.1 | 723.0 | 886.5 | 760.6 | 625.6 | 27.0 | 25.2 | 23.6 | 22.0 | 20.6 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 213.2 | 160.6 | 38.6 | 64.4 | 33.6 | 18.4 | 17.2 | 16.1 | 15.1 | 14.1 |
| Account Receivables, % | 91.46 | 42.8 | 7.95 | 169.31 | 116.59 | 68.44 | 68.44 | 68.44 | 68.44 | 68.44 |
| Inventories | 1.4 | 1.7 | 1.5 | 1.1 | .0 | .2 | .2 | .2 | .2 | .2 |
| Inventories, % | 0.60389 | 0.44563 | 0.3156 | 2.91 | 0 | 0.85527 | 0.85527 | 0.85527 | 0.85527 | 0.85527 |
| Accounts Payable | 7.3 | 14.9 | 14.8 | 25.5 | .0 | 4.2 | 3.9 | 3.6 | 3.4 | 3.2 |
| Accounts Payable, % | 3.14 | 3.98 | 3.05 | 67.08 | 0 | 15.45 | 15.45 | 15.45 | 15.45 | 15.45 |
| Capital Expenditure | -14.7 | -58.5 | -72.7 | -77.5 | -78.4 | -12.8 | -11.9 | -11.2 | -10.4 | -9.8 |
| Capital Expenditure, % | -6.29 | -15.58 | -14.97 | -203.83 | -271.9 | -47.37 | -47.37 | -47.37 | -47.37 | -47.37 |
| Tax Rate, % | 18.73 | 18.73 | 18.73 | 18.73 | 18.73 | 18.73 | 18.73 | 18.73 | 18.73 | 18.73 |
| EBITAT | 123.8 | 157.1 | 158.5 | -187.6 | -162.9 | -.8 | -.8 | -.7 | -.7 | -.6 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -92.9 | 175.9 | 241.0 | -248.9 | -144.0 | 16.0 | -1.9 | -1.8 | -1.7 | -1.6 |
| WACC, % | 5.93 | 5.92 | 5.91 | 5.96 | 5.95 | 5.93 | 5.93 | 5.93 | 5.93 | 5.93 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 9.3 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | -2 | |||||||||
| Terminal Value | -85 | |||||||||
| Present Terminal Value | -64 | |||||||||
| Enterprise Value | -55 | |||||||||
| Net Debt | -96 | |||||||||
| Equity Value | 41 | |||||||||
| Diluted Shares Outstanding, MM | 294 | |||||||||
| Equity Value Per Share | 0.14 |
What You Will Get
- Pre-Filled Financial Model: AbCellera’s actual data allows for accurate DCF valuation.
- Full Forecast Control: Modify revenue growth, profit margins, WACC, and other essential drivers.
- Instant Calculations: Real-time updates ensure you see the impact of your changes immediately.
- Investor-Ready Template: A polished Excel file crafted for high-quality valuation purposes.
- Customizable and Reusable: Designed for adaptability, enabling repeated application for in-depth forecasts.
Key Features
- Accurate Financial Data for AbCellera: Access reliable pre-loaded historical data and future forecasts specific to AbCellera Biologics Inc. (ABCL).
- Adjustable Forecast Parameters: Modify highlighted cells such as WACC, growth rates, and profit margins to suit your analysis.
- Automated Calculations: Instant updates to DCF, Net Present Value (NPV), and cash flow metrics.
- User-Friendly Dashboard: Clear charts and summaries for easy visualization of your valuation outcomes.
- Designed for All Levels: An intuitive layout tailored for investors, CFOs, and consultants alike.
How It Works
- Download the Template: Gain immediate access to the Excel-based ABCL DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and additional parameters.
- Instant Calculations: The model automatically refreshes AbCellera’s intrinsic value.
- Test Scenarios: Experiment with various assumptions to assess potential valuation shifts.
- Analyze and Decide: Utilize the results to inform your investment or financial analysis.
Why Choose This Calculator for AbCellera Biologics Inc. (ABCL)?
- User-Friendly Interface: Tailored for both novice users and seasoned professionals.
- Customizable Inputs: Adjust assumptions effortlessly to suit your financial analysis.
- Real-Time Valuation: Monitor immediate fluctuations in AbCellera’s valuation as you tweak the parameters.
- Preloaded Financials: Comes equipped with AbCellera’s latest financial data for swift evaluations.
- Relied Upon by Experts: A go-to tool for investors and analysts seeking to make educated choices.
Who Should Use This Product?
- Biotech Investors: Develop comprehensive and accurate valuation models for assessing AbCellera Biologics Inc. (ABCL).
- Corporate Strategy Teams: Evaluate valuation scenarios to inform strategic decisions within the biotech sector.
- Consultants and Advisors: Deliver precise valuation insights for clients interested in AbCellera Biologics Inc. (ABCL).
- Students and Educators: Utilize real-time data to practice and teach financial modeling in biotechnology.
- Healthcare Enthusiasts: Gain insights into how biotech companies like AbCellera Biologics Inc. (ABCL) are valued in the market.
What the Template Contains
- Preloaded ABCL Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.